Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04058197
Recruitment Status : Withdrawn (Lack of enrollment)
First Posted : August 15, 2019
Last Update Posted : December 2, 2021
Information provided by (Responsible Party):
TauTona Group

Brief Summary:

Approximately 60 subjects will be enrolled into this double-blind, placebo-controlled study for the Deferoxamine Intradermal Delivery Patch (DIDP).

Those subjects who pass Screening will enter into the 2-week Standard of Care (SOC) Run-In period. During this time, ulcers will be assessed to check healing based on digital planimetry, and qualitative features of the ulcer. Subjects who meet eligibility criteria at the end of the 2-week Run-in Period will be randomized into active and control groups (2 active to 1 placebo) and enter the 12-week Treatment Period. At each visit during the Treatment Period, the target ulcer will be measured by digital photographic planimetry, the Principal Investigator will assess the wound qualitative attributes, and the DIDP (or placebo patch) will be placed as the primary wound dressing. At each visit the subject will also receive/review a daily diary to document pain , study drug compliance, and analgesic use.

Condition or disease Intervention/treatment Phase
Chronic Cutaneous Ulcer Sickle Cell Disease Drug: Deferoxamine Product Other: Placebo Phase 1 Phase 2

Detailed Description:

Approximately 60 subjects will be enrolled to allow for up to 48 male or female subjects with SCD and cutaneous ulcers to complete this double-blind, placebo-controlled study.

A sentinel group of 3 subjects will be enrolled and evaluated for safety (while still blinded). The remaining subjects will be enrolled in a 2:1 ratio, active:placebo.

Those subjects who pass Screening will enter into the Standard of Care (SOC) Run-In period. During this time, ulcers will be assessed to check healing based on digital planimetry, and qualitative features of the ulcer. Subjects who meet eligibility criteria at the end of the Run-in Period will be randomized and enter the 12-week Treatment Period.

The DIDP (or placebo) will be replaced daily at home. The subject will visit the clinic on an approximately weekly basis for study assessments, to include imaging and planimetric wound measurements and qualitative wound assessments. Clinical laboratory samples will be collected at Treatment Baseline, Treatment Weeks 4, 8 and 12, or at End of Study (EOS) visit if sooner. A blood sample for PK testing will also be collected at these timepoints. During this Treatment Period, if at any time the wound has met the criterion for 100% healing, the subject will immediately go into the 4-week Follow-up Period.

During the Follow-up Period, the subject will come to the clinic at 1-week intervals. At these visits, the area of the wound will continue to be protected with a protective dressing. Clinical laboratory samples will be collected at the Termination Visit.

Ulcer pain will be assessed by the subject daily and recorded in a diary, along with a record of analgesic use. At each visit, study staff will assist the subjects to assign an overall ulcer pain score for the week.

Quality of Life Assessment will be performed at Baseline prior to dosing and at End of Treatment.

Safety will be assessed based upon known adverse outcomes of Deferoxamine (DFO) therapy. Skin will be examined for evidence of rash and skin irritation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of Deferoxamine Intradermal Delivery Patch (DIDP) in Chronic Sickle Cell Leg Ulcers
Actual Study Start Date : July 21, 2020
Actual Primary Completion Date : October 6, 2021
Actual Study Completion Date : October 6, 2021

Arm Intervention/treatment
Experimental: Active
Deferoxamine (DFO) Intradermal Delivery Patch (DIDP), 45mg DFO daily, up to 12 weeks
Drug: Deferoxamine Product
Deferoxamine Intradermal Delivery Patch

Placebo Comparator: Placebo
Other: Placebo
Placebo Patch

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [Safety / Tolerability] [ Time Frame: 12 weeks ]
    Incidence of systemic and local adverse events of DIDP applied to non-healing cutaneous leg ulcers. Changes from baseline characteristics that are treatment-related as measured by physical examinations, clinical laboratory, skin and other physiologic assessments.

Secondary Outcome Measures :
  1. Degree of Wound closure [ Time Frame: 12 weeks ]
    Percentage of wound closure

  2. Partial wound closure incidence [ Time Frame: 12 weeks ]
    Incidence of 80% closure

  3. Total wound closure incidence [ Time Frame: 12 weeks ]
    Incidence of 100% closure

  4. Wound closure rate [ Time Frame: 12 weeks ]
    rate of closure

  5. Ulcer recurrence [ Time Frame: 4 week follow-up post ]

Other Outcome Measures:
  1. Ulcer pain: Numeric Pain Rating Scale [ Time Frame: 12 weeks ]
    Numeric Pain Rating Scale (McCaffery et al, 1989) Scale: 0-10 (0 = no pain, 10 = severe pain)

  2. Analgesic use [ Time Frame: 12 weeks ]
    Diary: Opioid analgesic use converted as morphine mg equivalents (MME). Non-steroidal use will be descriptive.

  3. QOL: Health-related QOL in Chronic Wounds [ Time Frame: 12 weeks ]
    Wound QOL: Health-related QOL in Chronic Wounds (Augustin et el, 2014; Blome et al, 2014) Response range: "not at all" -to- "very much"

  4. Pharmacokinetics (blood) [ Time Frame: 12 weeks ]
    Deferoxamine / Placebo Peak plasma concentration (Cmax)

  5. Pharmacokinetics (blood) [ Time Frame: 12 weeks ]
    Deferoxamine / Placebo Time of peak plasma concentration (Tmax)

  6. Pharmacokinetics (blood) [ Time Frame: 8 hours ]
    Deferoxamine / Placebo Plasma concentration over 8 hours

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, >18 years of age
  2. Diagnosed with Sickle Cell Disease (SS, SC, Sß-thalassemia, SD, SOArab)
  3. Cutaneous ulcer with a University of Texas Wound Classification System Grade 1A or 2A (= Wagner class 1or 2, without infection or ischemia)
  4. Ulcer on lower leg, ankle, or dorsum of foot
  5. Vascular status of site assessed and judged adequate for healing (per Section 4.2)
  6. Ulcer present ≥ 14 days but not > 6 months at time of screening
  7. Ulcer 2.0 cm2 to 45.0 cm2 and < 6.0 cm diameter at widest point after debridement, prior to randomization.
  8. Ulcer healed by < 25% during the SOC run-in period prior to Visit 4 randomization.
  9. Subject is willing to use acceptable form of birth control (per Section 4.2) during trial and for one month thereafter

Exclusion Criteria:

  1. Active infection/purulence at ulcer site, based on Investigator's clinical judgement
  2. Current or history of osteomyelitis at or near site of ulcer
  3. Serum albumin < 2.0 g/dL
  4. Treatment with systemic DFO within 7 days of study entry
  5. Serum ferritin > 1000 ng/mL
  6. Subjects requiring, or expected to require, iron chelation therapy (systemic deferoxamine, deferasirox, or deferiprone) during the duration of the study.
  7. Subjects on dialysis or with evidence of nephrotic syndrome.
  8. Known bleeding or coagulation disorder that would preclude surgical debridement, as necessary.
  9. The subject has a major uncontrolled medical disorder, such as serious cardiovascular, renal, liver, pulmonary disease, or pulmonary disease (per Investigator discretion).
  10. Any condition that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study
  11. Previous participation in another clinical trial within 30 days prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04058197

Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Georgia
Sonar Clinical Research LLC
Atlanta, Georgia, United States, 30315
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Sponsors and Collaborators
TauTona Group
Layout table for additonal information
Responsible Party: TauTona Group Identifier: NCT04058197    
Other Study ID Numbers: CD1001
First Posted: August 15, 2019    Key Record Dates
Last Update Posted: December 2, 2021
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by TauTona Group:
chronic sickle cell leg ulcer
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Leg Ulcer
Skin Ulcer
Pathologic Processes
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn
Skin Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action